Targeting pancreatic cancer cells to improve treatment outcomes
Targeting Pancreatic Cancer Senescence with ImmunoPET
This study is exploring a new way to treat pancreatic cancer by focusing on certain aging cells that might help tumors grow and resist treatment, using special imaging techniques to find these cells, with the hope of creating better treatment options that could improve survival and quality of life for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11074699 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating pancreatic cancer by targeting senescent cells, which can contribute to tumor growth and resistance to therapy. The study utilizes advanced imaging techniques, specifically ImmunoPET, to identify these senescent cells and assess their role in the disease. By using antibody-based agents, the research aims to enhance the specificity of detection and potentially improve treatment strategies through targeted therapies. Patients may benefit from new therapeutic combinations that could lead to better survival rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer who are undergoing or have undergone chemotherapy.
Not a fit: Patients with early-stage pancreatic cancer who have not yet started treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting senescent cells in cancer treatment, suggesting that this approach could be a significant advancement in pancreatic cancer therapy.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Pratt, Edwin Charles — Sloan-Kettering Inst Can Research
- Study coordinator: Pratt, Edwin Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.